文献速递肝病消化道肿瘤与早癌

持续病毒学应答后肝细胞癌患者临床表现与预后的区域差异

Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-07-11

该研究纳入欧洲、北美、南美、中东、南亚、东亚和东南亚30个中心的8796例晚期纤维化或肝硬化并获得持续病毒学应答的患者,其中583例(6.6%)发生持续病毒学应答后肝细胞癌。不同区域在监测检出比例、肿瘤直径、多结节比例及生存率上差异显著,监测与早期检出和较低死亡率相关。

要点

  • 持续病毒学应答后肝细胞癌监测检出比例区域间范围为59.5%-100%。
  • 中位最大肿瘤直径区域间范围为1.8-5.0 cm,多结节肝细胞癌比例范围为15.4%-60.8%。
  • 监测与早期检出相关(巴塞罗那临床肝癌分期0/A期:71.0% vs 21.3%;P < .0001)及较低死亡率(校正风险比0.29;95% CI,0.18-0.46)。

核心结论

  • 持续病毒学应答后肝细胞癌的临床特征(包括早期检出)和预后在不同地理区域间存在显著差异。
  • 监测利用似乎是改善全球持续病毒学应答后肝细胞癌患者预后的高产出干预靶点。

研究设计与样本

  • 研究识别2015年3月至2021年10月期间来自欧洲、北美、南美、中东、南亚、东亚和东南亚30个中心的晚期纤维化(F3/F4)并发生持续病毒学应答后肝细胞癌的患者。
  • 比较不同区域的患者人口学特征、肝功能障碍和肿瘤负荷,采用Kaplan-Meier分析比较不同区域的总生存率,并使用多变量Cox回归分析识别与生存相关的因素。

主要发现

  • 在8796例获得持续病毒学应答的晚期纤维化或肝硬化患者中,583例(6.6%)发生新发肝细胞癌。
  • 监测检出患者比例区域间范围为59.5%-100%,中位最大肿瘤直径范围为1.8-5.0 cm,多结节肝细胞癌比例范围为15.4%-60.8%。
  • 患者预后区域间差异很大(风险比范围1.82-9.92),东亚、北美和南美生存率最高,中东和南亚生存率最低。
  • 校正地理区域后,肝细胞癌监测与早期检出相关(巴塞罗那临床肝癌分期0/A期:71.0% vs 21.3%;P < .0001)和较低死亡率相关(校正风险比0.29;95% CI,0.18-0.46)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Widespread use of direct-acting antivirals for hepatitis C virus infection has been paralleled with increased numbers of patients with hepatocellular carcinoma (HCC) after achieving sustained virologic response (post-SVR HCC) worldwide. Few data compare regional differences in the presentation and prognosis of patients with post-SVR HCC. METHODS: We identified patients with advanced fibrosis (F3/F4) who developed incident post-SVR HCC between March 2015 and October 2021 from 30 sites in Europe, North America, South America, the Middle East, South Asia, East Asia, and Southeast Asia. We compared patient demographics, liver dysfunction, and tumor burden by region. We compared overall survival by region using Kaplan-Meier analysis and identified factors associated with survival using multivariable Cox regression analysis. RESULTS: Among 8796 patients with advanced fibrosis or cirrhosis who achieved SVR, 583 (6.6%) developed incident HCC. There was marked regional variation in the proportion of patients detected by surveillance (range: 59.5%-100%), median maximum tumor diameter (range, 1.8-5.0 cm), and the proportion with multinodular HCC (range, 15.4%-60.8%). The prognosis of patients highly varied by region (hazard ratio range, 1.82-9.92), with the highest survival rates in East Asia, North America, and South America, and the lowest survival rates in the Middle East and South Asia. After adjusting for geographic region, HCC surveillance was associated with early stage detection (Barcelona Clinic Liver Cancer stage 0/A, 71.0% vs 21.3%; P < .0001) and lower mortality rates (adjusted hazard ratio, 0.29; 95% CI, 0.18-0.46). CONCLUSIONS: Clinical characteristics, including early stage detection, and prognosis of post-SVR HCC differed significantly across geographic regions. Surveillance utilization appears to be a high-yield intervention target to improve prognosis among patients with post-SVR HCC globally.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Toyoda H, Kanneganti M, Melendez-Torres J, et al. Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2023. PMID: 37442316. doi:10.1016/j.cgh.2023.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。